Application effects of remimazolam and propofol on elderly patients undergoing hip replacement

Objective To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and circulatory systems, stress and cognitive function. Methods Sixty elderly patients undergoing elective hip replacement in the hosp...

Full description

Saved in:
Bibliographic Details
Published inBMC anesthesiology Vol. 22; no. 1; pp. 118 - 10
Main Authors Zhang, Junbao, Wang, Xin, Zhang, Qing, Wang, Zicheng, Zhu, Shoufeng
Format Journal Article
LanguageEnglish
Published London BioMed Central 23.04.2022
BioMed Central Ltd
BMC
Subjects
Online AccessGet full text
ISSN1471-2253
1471-2253
DOI10.1186/s12871-022-01641-5

Cover

Abstract Objective To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and circulatory systems, stress and cognitive function. Methods Sixty elderly patients undergoing elective hip replacement in the hospital were selected as the research subjects, and they were divided into the remimazolam group and the propofol group according to the admission sequence of patients. The remimazolam group was anesthetized with remimazolam, and the propofol group was anesthetized with propofol. The anesthesia-related indicators, perioperative pain degree [Visual Analogue Scale (VAS)], circulatory indicators [heart rate, mean arterial pressure (MAP)] before anesthesia (T 0 ), immediately before laryngeal mask insertion (T 1 ), at 5 min after laryngeal mask insertion (T 2 ), at 30 min after laryngeal mask insertion (T 3 ) and at 5 min after laryngeal mask removal (T 4 ), stress response indicators (plasma epinephrine, norepinephrine, cortisol) before anesthesia induction and at 24 h and 72 h after surgery, cognitive function [Mini-Mental State Examination (MMSE)] and adverse reactions were compared between the two groups. Results Among the 60 enrolled patients, only 1 case was excluded due to withdrawal, thus 30 cases in the remimazolam group and 29 cases in the propofol group were included. There were statistically significant differences in the heart rate, MAP, plasma epinephrine, norepinephrine, cortisol and VAS score in the two groups from the aspects of interaction effect and time-point effect ( P  < 0.05). The heart rate and MAP at T 1 , T 2 and T 3 in the two groups were significantly decreased compared with those at T 0 , but the heart rate and MAP in the remimazolam group at T 1 , T 2 and T 3 were significantly higher than those in the propofol group ( P  < 0.05). There were no statistical differences in the anesthesia time, awakening time and extubation time between the remimazolam group and the propofol group ( P  > 0.05). The levels of plasma epinephrine, norepinephrine and cortisol in the two groups were significantly higher at 24 h and 72 h after surgery than those before anesthesia induction, and the above levels were significantly lower in the remimazolam group than those in the propofol group ( P  < 0.05). The VAS scores at each time point in the two groups were significantly reduced compared to before surgery, but there was no statistically significant difference between the two groups after surgery ( P  > 0.05). The MMSE scores of the two groups were significantly lower at 1 d and 3 d after surgery compared with those before anesthesia induction, but the score in the remimazolam group was significantly higher than that in the propofol group ( P  < 0.05). In addition, the incidence rates of adverse reactions were significantly lower in the remimazolam group compared to the propofol group ( P  < 0.05). Conclusion Compared with propofol, remimazolam can achieve equivalent anesthetic and analgesic effects in elderly patients undergoing hip replacement. However, the latter one can significantly relieve respiratory and circulatory suppression, stress response and cognitive dysfunction, with good safety. Trial registration This single-center, prospective, RCT has completed the registration of the Chinese Clinical Trial Center at 31/12/2021 with the registration number ChiCTR2100055039 .
AbstractList To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and circulatory systems, stress and cognitive function.OBJECTIVETo explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and circulatory systems, stress and cognitive function.Sixty elderly patients undergoing elective hip replacement in the hospital were selected as the research subjects, and they were divided into the remimazolam group and the propofol group according to the admission sequence of patients. The remimazolam group was anesthetized with remimazolam, and the propofol group was anesthetized with propofol. The anesthesia-related indicators, perioperative pain degree [Visual Analogue Scale (VAS)], circulatory indicators [heart rate, mean arterial pressure (MAP)] before anesthesia (T0), immediately before laryngeal mask insertion (T1), at 5 min after laryngeal mask insertion (T2), at 30 min after laryngeal mask insertion (T3) and at 5 min after laryngeal mask removal (T4), stress response indicators (plasma epinephrine, norepinephrine, cortisol) before anesthesia induction and at 24 h and 72 h after surgery, cognitive function [Mini-Mental State Examination (MMSE)] and adverse reactions were compared between the two groups.METHODSSixty elderly patients undergoing elective hip replacement in the hospital were selected as the research subjects, and they were divided into the remimazolam group and the propofol group according to the admission sequence of patients. The remimazolam group was anesthetized with remimazolam, and the propofol group was anesthetized with propofol. The anesthesia-related indicators, perioperative pain degree [Visual Analogue Scale (VAS)], circulatory indicators [heart rate, mean arterial pressure (MAP)] before anesthesia (T0), immediately before laryngeal mask insertion (T1), at 5 min after laryngeal mask insertion (T2), at 30 min after laryngeal mask insertion (T3) and at 5 min after laryngeal mask removal (T4), stress response indicators (plasma epinephrine, norepinephrine, cortisol) before anesthesia induction and at 24 h and 72 h after surgery, cognitive function [Mini-Mental State Examination (MMSE)] and adverse reactions were compared between the two groups.Among the 60 enrolled patients, only 1 case was excluded due to withdrawal, thus 30 cases in the remimazolam group and 29 cases in the propofol group were included. There were statistically significant differences in the heart rate, MAP, plasma epinephrine, norepinephrine, cortisol and VAS score in the two groups from the aspects of interaction effect and time-point effect (P < 0.05). The heart rate and MAP at T1, T2 and T3 in the two groups were significantly decreased compared with those at T0, but the heart rate and MAP in the remimazolam group at T1, T2 and T3 were significantly higher than those in the propofol group (P < 0.05). There were no statistical differences in the anesthesia time, awakening time and extubation time between the remimazolam group and the propofol group (P > 0.05). The levels of plasma epinephrine, norepinephrine and cortisol in the two groups were significantly higher at 24 h and 72 h after surgery than those before anesthesia induction, and the above levels were significantly lower in the remimazolam group than those in the propofol group (P < 0.05). The VAS scores at each time point in the two groups were significantly reduced compared to before surgery, but there was no statistically significant difference between the two groups after surgery (P > 0.05). The MMSE scores of the two groups were significantly lower at 1 d and 3 d after surgery compared with those before anesthesia induction, but the score in the remimazolam group was significantly higher than that in the propofol group (P < 0.05). In addition, the incidence rates of adverse reactions were significantly lower in the remimazolam group compared to the propofol group (P < 0.05).RESULTSAmong the 60 enrolled patients, only 1 case was excluded due to withdrawal, thus 30 cases in the remimazolam group and 29 cases in the propofol group were included. There were statistically significant differences in the heart rate, MAP, plasma epinephrine, norepinephrine, cortisol and VAS score in the two groups from the aspects of interaction effect and time-point effect (P < 0.05). The heart rate and MAP at T1, T2 and T3 in the two groups were significantly decreased compared with those at T0, but the heart rate and MAP in the remimazolam group at T1, T2 and T3 were significantly higher than those in the propofol group (P < 0.05). There were no statistical differences in the anesthesia time, awakening time and extubation time between the remimazolam group and the propofol group (P > 0.05). The levels of plasma epinephrine, norepinephrine and cortisol in the two groups were significantly higher at 24 h and 72 h after surgery than those before anesthesia induction, and the above levels were significantly lower in the remimazolam group than those in the propofol group (P < 0.05). The VAS scores at each time point in the two groups were significantly reduced compared to before surgery, but there was no statistically significant difference between the two groups after surgery (P > 0.05). The MMSE scores of the two groups were significantly lower at 1 d and 3 d after surgery compared with those before anesthesia induction, but the score in the remimazolam group was significantly higher than that in the propofol group (P < 0.05). In addition, the incidence rates of adverse reactions were significantly lower in the remimazolam group compared to the propofol group (P < 0.05).Compared with propofol, remimazolam can achieve equivalent anesthetic and analgesic effects in elderly patients undergoing hip replacement. However, the latter one can significantly relieve respiratory and circulatory suppression, stress response and cognitive dysfunction, with good safety.CONCLUSIONCompared with propofol, remimazolam can achieve equivalent anesthetic and analgesic effects in elderly patients undergoing hip replacement. However, the latter one can significantly relieve respiratory and circulatory suppression, stress response and cognitive dysfunction, with good safety.This single-center, prospective, RCT has completed the registration of the Chinese Clinical Trial Center at 31/12/2021 with the registration number ChiCTR2100055039 .TRIAL REGISTRATIONThis single-center, prospective, RCT has completed the registration of the Chinese Clinical Trial Center at 31/12/2021 with the registration number ChiCTR2100055039 .
Objective To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and circulatory systems, stress and cognitive function. Methods Sixty elderly patients undergoing elective hip replacement in the hospital were selected as the research subjects, and they were divided into the remimazolam group and the propofol group according to the admission sequence of patients. The remimazolam group was anesthetized with remimazolam, and the propofol group was anesthetized with propofol. The anesthesia-related indicators, perioperative pain degree [Visual Analogue Scale (VAS)], circulatory indicators [heart rate, mean arterial pressure (MAP)] before anesthesia (T 0 ), immediately before laryngeal mask insertion (T 1 ), at 5 min after laryngeal mask insertion (T 2 ), at 30 min after laryngeal mask insertion (T 3 ) and at 5 min after laryngeal mask removal (T 4 ), stress response indicators (plasma epinephrine, norepinephrine, cortisol) before anesthesia induction and at 24 h and 72 h after surgery, cognitive function [Mini-Mental State Examination (MMSE)] and adverse reactions were compared between the two groups. Results Among the 60 enrolled patients, only 1 case was excluded due to withdrawal, thus 30 cases in the remimazolam group and 29 cases in the propofol group were included. There were statistically significant differences in the heart rate, MAP, plasma epinephrine, norepinephrine, cortisol and VAS score in the two groups from the aspects of interaction effect and time-point effect ( P  < 0.05). The heart rate and MAP at T 1 , T 2 and T 3 in the two groups were significantly decreased compared with those at T 0 , but the heart rate and MAP in the remimazolam group at T 1 , T 2 and T 3 were significantly higher than those in the propofol group ( P  < 0.05). There were no statistical differences in the anesthesia time, awakening time and extubation time between the remimazolam group and the propofol group ( P  > 0.05). The levels of plasma epinephrine, norepinephrine and cortisol in the two groups were significantly higher at 24 h and 72 h after surgery than those before anesthesia induction, and the above levels were significantly lower in the remimazolam group than those in the propofol group ( P  < 0.05). The VAS scores at each time point in the two groups were significantly reduced compared to before surgery, but there was no statistically significant difference between the two groups after surgery ( P  > 0.05). The MMSE scores of the two groups were significantly lower at 1 d and 3 d after surgery compared with those before anesthesia induction, but the score in the remimazolam group was significantly higher than that in the propofol group ( P  < 0.05). In addition, the incidence rates of adverse reactions were significantly lower in the remimazolam group compared to the propofol group ( P  < 0.05). Conclusion Compared with propofol, remimazolam can achieve equivalent anesthetic and analgesic effects in elderly patients undergoing hip replacement. However, the latter one can significantly relieve respiratory and circulatory suppression, stress response and cognitive dysfunction, with good safety. Trial registration This single-center, prospective, RCT has completed the registration of the Chinese Clinical Trial Center at 31/12/2021 with the registration number ChiCTR2100055039 .
Objective To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and circulatory systems, stress and cognitive function. Methods Sixty elderly patients undergoing elective hip replacement in the hospital were selected as the research subjects, and they were divided into the remimazolam group and the propofol group according to the admission sequence of patients. The remimazolam group was anesthetized with remimazolam, and the propofol group was anesthetized with propofol. The anesthesia-related indicators, perioperative pain degree [Visual Analogue Scale (VAS)], circulatory indicators [heart rate, mean arterial pressure (MAP)] before anesthesia (T.sub.0), immediately before laryngeal mask insertion (T.sub.1), at 5 min after laryngeal mask insertion (T.sub.2), at 30 min after laryngeal mask insertion (T.sub.3) and at 5 min after laryngeal mask removal (T.sub.4), stress response indicators (plasma epinephrine, norepinephrine, cortisol) before anesthesia induction and at 24 h and 72 h after surgery, cognitive function [Mini-Mental State Examination (MMSE)] and adverse reactions were compared between the two groups. Results Among the 60 enrolled patients, only 1 case was excluded due to withdrawal, thus 30 cases in the remimazolam group and 29 cases in the propofol group were included. There were statistically significant differences in the heart rate, MAP, plasma epinephrine, norepinephrine, cortisol and VAS score in the two groups from the aspects of interaction effect and time-point effect (P < 0.05). The heart rate and MAP at T.sub.1, T.sub.2 and T.sub.3 in the two groups were significantly decreased compared with those at T.sub.0, but the heart rate and MAP in the remimazolam group at T.sub.1, T.sub.2 and T.sub.3 were significantly higher than those in the propofol group (P < 0.05). There were no statistical differences in the anesthesia time, awakening time and extubation time between the remimazolam group and the propofol group (P > 0.05). The levels of plasma epinephrine, norepinephrine and cortisol in the two groups were significantly higher at 24 h and 72 h after surgery than those before anesthesia induction, and the above levels were significantly lower in the remimazolam group than those in the propofol group (P < 0.05). The VAS scores at each time point in the two groups were significantly reduced compared to before surgery, but there was no statistically significant difference between the two groups after surgery (P > 0.05). The MMSE scores of the two groups were significantly lower at 1 d and 3 d after surgery compared with those before anesthesia induction, but the score in the remimazolam group was significantly higher than that in the propofol group (P < 0.05). In addition, the incidence rates of adverse reactions were significantly lower in the remimazolam group compared to the propofol group (P < 0.05). Conclusion Compared with propofol, remimazolam can achieve equivalent anesthetic and analgesic effects in elderly patients undergoing hip replacement. However, the latter one can significantly relieve respiratory and circulatory suppression, stress response and cognitive dysfunction, with good safety. Trial registration This single-center, prospective, RCT has completed the registration of the Chinese Clinical Trial Center at 31/12/2021 with the registration number ChiCTR2100055039. Keywords: Remimazolam, Propofol, Hip replacement, Elderly
To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and circulatory systems, stress and cognitive function. Sixty elderly patients undergoing elective hip replacement in the hospital were selected as the research subjects, and they were divided into the remimazolam group and the propofol group according to the admission sequence of patients. The remimazolam group was anesthetized with remimazolam, and the propofol group was anesthetized with propofol. The anesthesia-related indicators, perioperative pain degree [Visual Analogue Scale (VAS)], circulatory indicators [heart rate, mean arterial pressure (MAP)] before anesthesia (T.sub.0), immediately before laryngeal mask insertion (T.sub.1), at 5 min after laryngeal mask insertion (T.sub.2), at 30 min after laryngeal mask insertion (T.sub.3) and at 5 min after laryngeal mask removal (T.sub.4), stress response indicators (plasma epinephrine, norepinephrine, cortisol) before anesthesia induction and at 24 h and 72 h after surgery, cognitive function [Mini-Mental State Examination (MMSE)] and adverse reactions were compared between the two groups. Among the 60 enrolled patients, only 1 case was excluded due to withdrawal, thus 30 cases in the remimazolam group and 29 cases in the propofol group were included. There were statistically significant differences in the heart rate, MAP, plasma epinephrine, norepinephrine, cortisol and VAS score in the two groups from the aspects of interaction effect and time-point effect (P < 0.05). The heart rate and MAP at T.sub.1, T.sub.2 and T.sub.3 in the two groups were significantly decreased compared with those at T.sub.0, but the heart rate and MAP in the remimazolam group at T.sub.1, T.sub.2 and T.sub.3 were significantly higher than those in the propofol group (P < 0.05). There were no statistical differences in the anesthesia time, awakening time and extubation time between the remimazolam group and the propofol group (P > 0.05). The levels of plasma epinephrine, norepinephrine and cortisol in the two groups were significantly higher at 24 h and 72 h after surgery than those before anesthesia induction, and the above levels were significantly lower in the remimazolam group than those in the propofol group (P < 0.05). The VAS scores at each time point in the two groups were significantly reduced compared to before surgery, but there was no statistically significant difference between the two groups after surgery (P > 0.05). The MMSE scores of the two groups were significantly lower at 1 d and 3 d after surgery compared with those before anesthesia induction, but the score in the remimazolam group was significantly higher than that in the propofol group (P < 0.05). In addition, the incidence rates of adverse reactions were significantly lower in the remimazolam group compared to the propofol group (P < 0.05). Compared with propofol, remimazolam can achieve equivalent anesthetic and analgesic effects in elderly patients undergoing hip replacement. However, the latter one can significantly relieve respiratory and circulatory suppression, stress response and cognitive dysfunction, with good safety.
Abstract Objective To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and circulatory systems, stress and cognitive function. Methods Sixty elderly patients undergoing elective hip replacement in the hospital were selected as the research subjects, and they were divided into the remimazolam group and the propofol group according to the admission sequence of patients. The remimazolam group was anesthetized with remimazolam, and the propofol group was anesthetized with propofol. The anesthesia-related indicators, perioperative pain degree [Visual Analogue Scale (VAS)], circulatory indicators [heart rate, mean arterial pressure (MAP)] before anesthesia (T0), immediately before laryngeal mask insertion (T1), at 5 min after laryngeal mask insertion (T2), at 30 min after laryngeal mask insertion (T3) and at 5 min after laryngeal mask removal (T4), stress response indicators (plasma epinephrine, norepinephrine, cortisol) before anesthesia induction and at 24 h and 72 h after surgery, cognitive function [Mini-Mental State Examination (MMSE)] and adverse reactions were compared between the two groups. Results Among the 60 enrolled patients, only 1 case was excluded due to withdrawal, thus 30 cases in the remimazolam group and 29 cases in the propofol group were included. There were statistically significant differences in the heart rate, MAP, plasma epinephrine, norepinephrine, cortisol and VAS score in the two groups from the aspects of interaction effect and time-point effect (P < 0.05). The heart rate and MAP at T1, T2 and T3 in the two groups were significantly decreased compared with those at T0, but the heart rate and MAP in the remimazolam group at T1, T2 and T3 were significantly higher than those in the propofol group (P < 0.05). There were no statistical differences in the anesthesia time, awakening time and extubation time between the remimazolam group and the propofol group (P > 0.05). The levels of plasma epinephrine, norepinephrine and cortisol in the two groups were significantly higher at 24 h and 72 h after surgery than those before anesthesia induction, and the above levels were significantly lower in the remimazolam group than those in the propofol group (P < 0.05). The VAS scores at each time point in the two groups were significantly reduced compared to before surgery, but there was no statistically significant difference between the two groups after surgery (P > 0.05). The MMSE scores of the two groups were significantly lower at 1 d and 3 d after surgery compared with those before anesthesia induction, but the score in the remimazolam group was significantly higher than that in the propofol group (P < 0.05). In addition, the incidence rates of adverse reactions were significantly lower in the remimazolam group compared to the propofol group (P < 0.05). Conclusion Compared with propofol, remimazolam can achieve equivalent anesthetic and analgesic effects in elderly patients undergoing hip replacement. However, the latter one can significantly relieve respiratory and circulatory suppression, stress response and cognitive dysfunction, with good safety. Trial registration This single-center, prospective, RCT has completed the registration of the Chinese Clinical Trial Center at 31/12/2021 with the registration number ChiCTR2100055039 .
Objective To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and circulatory systems, stress and cognitive function. Methods Sixty elderly patients undergoing elective hip replacement in the hospital were selected as the research subjects, and they were divided into the remimazolam group and the propofol group according to the admission sequence of patients. The remimazolam group was anesthetized with remimazolam, and the propofol group was anesthetized with propofol. The anesthesia-related indicators, perioperative pain degree [Visual Analogue Scale (VAS)], circulatory indicators [heart rate, mean arterial pressure (MAP)] before anesthesia (T0), immediately before laryngeal mask insertion (T1), at 5 min after laryngeal mask insertion (T2), at 30 min after laryngeal mask insertion (T3) and at 5 min after laryngeal mask removal (T4), stress response indicators (plasma epinephrine, norepinephrine, cortisol) before anesthesia induction and at 24 h and 72 h after surgery, cognitive function [Mini-Mental State Examination (MMSE)] and adverse reactions were compared between the two groups. Results Among the 60 enrolled patients, only 1 case was excluded due to withdrawal, thus 30 cases in the remimazolam group and 29 cases in the propofol group were included. There were statistically significant differences in the heart rate, MAP, plasma epinephrine, norepinephrine, cortisol and VAS score in the two groups from the aspects of interaction effect and time-point effect (P < 0.05). The heart rate and MAP at T1, T2 and T3 in the two groups were significantly decreased compared with those at T0, but the heart rate and MAP in the remimazolam group at T1, T2 and T3 were significantly higher than those in the propofol group (P < 0.05). There were no statistical differences in the anesthesia time, awakening time and extubation time between the remimazolam group and the propofol group (P > 0.05). The levels of plasma epinephrine, norepinephrine and cortisol in the two groups were significantly higher at 24 h and 72 h after surgery than those before anesthesia induction, and the above levels were significantly lower in the remimazolam group than those in the propofol group (P < 0.05). The VAS scores at each time point in the two groups were significantly reduced compared to before surgery, but there was no statistically significant difference between the two groups after surgery (P > 0.05). The MMSE scores of the two groups were significantly lower at 1 d and 3 d after surgery compared with those before anesthesia induction, but the score in the remimazolam group was significantly higher than that in the propofol group (P < 0.05). In addition, the incidence rates of adverse reactions were significantly lower in the remimazolam group compared to the propofol group (P < 0.05). Conclusion Compared with propofol, remimazolam can achieve equivalent anesthetic and analgesic effects in elderly patients undergoing hip replacement. However, the latter one can significantly relieve respiratory and circulatory suppression, stress response and cognitive dysfunction, with good safety. Trial registration This single-center, prospective, RCT has completed the registration of the Chinese Clinical Trial Center at 31/12/2021 with the registration number ChiCTR2100055039.
To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and circulatory systems, stress and cognitive function. Sixty elderly patients undergoing elective hip replacement in the hospital were selected as the research subjects, and they were divided into the remimazolam group and the propofol group according to the admission sequence of patients. The remimazolam group was anesthetized with remimazolam, and the propofol group was anesthetized with propofol. The anesthesia-related indicators, perioperative pain degree [Visual Analogue Scale (VAS)], circulatory indicators [heart rate, mean arterial pressure (MAP)] before anesthesia (T ), immediately before laryngeal mask insertion (T ), at 5 min after laryngeal mask insertion (T ), at 30 min after laryngeal mask insertion (T ) and at 5 min after laryngeal mask removal (T ), stress response indicators (plasma epinephrine, norepinephrine, cortisol) before anesthesia induction and at 24 h and 72 h after surgery, cognitive function [Mini-Mental State Examination (MMSE)] and adverse reactions were compared between the two groups. Among the 60 enrolled patients, only 1 case was excluded due to withdrawal, thus 30 cases in the remimazolam group and 29 cases in the propofol group were included. There were statistically significant differences in the heart rate, MAP, plasma epinephrine, norepinephrine, cortisol and VAS score in the two groups from the aspects of interaction effect and time-point effect (P < 0.05). The heart rate and MAP at T , T and T in the two groups were significantly decreased compared with those at T , but the heart rate and MAP in the remimazolam group at T , T and T were significantly higher than those in the propofol group (P < 0.05). There were no statistical differences in the anesthesia time, awakening time and extubation time between the remimazolam group and the propofol group (P > 0.05). The levels of plasma epinephrine, norepinephrine and cortisol in the two groups were significantly higher at 24 h and 72 h after surgery than those before anesthesia induction, and the above levels were significantly lower in the remimazolam group than those in the propofol group (P < 0.05). The VAS scores at each time point in the two groups were significantly reduced compared to before surgery, but there was no statistically significant difference between the two groups after surgery (P > 0.05). The MMSE scores of the two groups were significantly lower at 1 d and 3 d after surgery compared with those before anesthesia induction, but the score in the remimazolam group was significantly higher than that in the propofol group (P < 0.05). In addition, the incidence rates of adverse reactions were significantly lower in the remimazolam group compared to the propofol group (P < 0.05). Compared with propofol, remimazolam can achieve equivalent anesthetic and analgesic effects in elderly patients undergoing hip replacement. However, the latter one can significantly relieve respiratory and circulatory suppression, stress response and cognitive dysfunction, with good safety. This single-center, prospective, RCT has completed the registration of the Chinese Clinical Trial Center at 31/12/2021 with the registration number ChiCTR2100055039 .
ArticleNumber 118
Audience Academic
Author Wang, Zicheng
Zhu, Shoufeng
Zhang, Junbao
Zhang, Qing
Wang, Xin
Author_xml – sequence: 1
  givenname: Junbao
  surname: Zhang
  fullname: Zhang, Junbao
  organization: Department of Anesthesiology, The Second People’s Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University
– sequence: 2
  givenname: Xin
  surname: Wang
  fullname: Wang, Xin
  email: anaesthes@126.com
  organization: Department of Anesthesiology, The Second People’s Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University
– sequence: 3
  givenname: Qing
  surname: Zhang
  fullname: Zhang, Qing
  organization: Department of Anesthesiology, The Second People’s Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University
– sequence: 4
  givenname: Zicheng
  surname: Wang
  fullname: Wang, Zicheng
  organization: Department of Anesthesiology, The Second People’s Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University
– sequence: 5
  givenname: Shoufeng
  surname: Zhu
  fullname: Zhu, Shoufeng
  organization: Department of Anesthesiology, The Second People’s Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35461223$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAUhSNURB_wB1igSGzYpPgdZ4M0qnhUqsQGtlgex049cuxgJ5XKr-fOTGk7FWqySHL9neN7nXNaHcUUbVW9xegcYyk-FkxkixtESIOwYLjhL6oTzKBECKdHj96Pq9NSNgjhViL6qjqmnAlMCD2pfq2mKXijZ59ibZ2zZi51cnW2ox_1nxT0WOvY11NOU3Ip1Fss9DaH23oClY3ALxEKQ_JxqK_9BNopaGNHWHtdvXQ6FPvm7nlW_fzy-cfFt-bq-9fLi9VVY7iUvHG6ly3Sgq6p5Rhr44iAL-gWay1Qt0Zda1tkjGWOGQxTW0GxY_3aES4Yo2fV5d63T3qjpgy951uVtFe7QsqD0nn2JlhFDO5F1xKKmGCoN1pTjozkRCJJZUfA69Pea1rWo-0NjJF1ODA9XIn-Wg3pRnWIMi4oGHy4M8jp92LLrEZfjA1BR5uWoojgHCPWtQjQ90_QTVpyhKMCCi4qEKYP1KBhAB9dgn3N1lStWoQZQW0ngTr_DwV3D__SQHSch_qB4N3jQe8n_JcOAMgeMDmVkq27RzBS2wiqfQQVRFDtIqg4iOQTkfHzLl_Qjg_PS-leWmCfONj8cBrPqP4Cn5Dt4Q
CitedBy_id crossref_primary_10_3389_fmed_2024_1331103
crossref_primary_10_1136_bmjopen_2023_071912
crossref_primary_10_23736_S0375_9393_24_18041_8
crossref_primary_10_2147_DDDT_S419146
crossref_primary_10_1016_j_jcadva_2024_100041
crossref_primary_10_12677_ACM_2023_13112553
crossref_primary_10_2147_DDDT_S473700
crossref_primary_10_1097_EJA_0000000000002042
crossref_primary_10_2147_DDDT_S425590
crossref_primary_10_23736_S0375_9393_23_17034_9
crossref_primary_10_1007_s00101_024_01454_w
crossref_primary_10_1007_s00540_022_03148_2
crossref_primary_10_1016_j_clinthera_2024_09_020
crossref_primary_10_1186_s40981_024_00716_1
crossref_primary_10_2147_DDDT_S474275
crossref_primary_10_1186_s12871_023_01974_9
crossref_primary_10_1097_MD_0000000000037199
crossref_primary_10_3389_fmed_2023_1288243
crossref_primary_10_1097_EJA_0000000000002107
crossref_primary_10_1016_j_jclinane_2023_111367
crossref_primary_10_1007_s12325_024_02820_1
crossref_primary_10_1590_acb399324
crossref_primary_10_3390_jcm12010257
crossref_primary_10_3389_fmed_2023_1265860
crossref_primary_10_1111_aas_14588
crossref_primary_10_3389_fmed_2025_1409495
crossref_primary_10_58888_2957_3912_2023_03_01
crossref_primary_10_2147_DDDT_S401969
crossref_primary_10_1186_s40981_023_00662_4
crossref_primary_10_1016_j_bja_2023_11_045
crossref_primary_10_1186_s12871_022_01805_3
crossref_primary_10_3390_jcm13154362
crossref_primary_10_1016_j_heliyon_2024_e25399
crossref_primary_10_2147_DDDT_S489167
crossref_primary_10_1016_j_brainresbull_2023_110821
crossref_primary_10_1053_j_jvca_2024_08_038
crossref_primary_10_1136_rapm_2023_104415
crossref_primary_10_3390_jcm12165285
crossref_primary_10_2147_DDDT_S456675
crossref_primary_10_3389_fphar_2024_1427755
crossref_primary_10_1016_j_jclinane_2023_111356
crossref_primary_10_1097_EJA_0000000000001902
crossref_primary_10_1053_j_jvca_2023_06_027
crossref_primary_10_1213_ANE_0000000000007309
crossref_primary_10_3390_jcm12237316
Cites_doi 10.1177/2151459318816482
10.1002/phar.1806
10.1155/2020/5602683
10.1186/s12871-018-0633-2
10.12998/wjcc.v9.i34.10595
10.1097/ALN.0000000000003103
10.1055/a-0829-6284
10.1016/j.gie.2020.03.002
10.1007/s00540-020-02788-6
10.1097/ACO.0000000000000877
10.1097/MD.0000000000014925
10.1016/j.yebeh.2015.08.012
10.1007/s40265-021-01544-8
10.1002/acr.23838
10.1080/03602530902722679
10.3233/JAD-160119
10.1016/j.arth.2020.06.085
10.2147/JPR.S282462
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12871-022-01641-5
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic




Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2253
EndPage 10
ExternalDocumentID oai_doaj_org_article_2c1d6972304640dcaa350c8528083892
PMC9034563
A701420798
35461223
10_1186_s12871_022_01641_5
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
0R~
23N
2WC
53G
5GY
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
~8M
AAYXX
ALIPV
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7TK
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c5885-fad870a63b3e511acf26a637801aa609b097e70cce4f4c1871e631f4dbf256443
IEDL.DBID C6C
ISSN 1471-2253
IngestDate Wed Aug 27 01:13:20 EDT 2025
Thu Aug 21 18:34:00 EDT 2025
Fri Sep 05 10:24:45 EDT 2025
Fri Jul 25 07:37:57 EDT 2025
Tue Jun 17 21:46:08 EDT 2025
Tue Jun 10 20:11:16 EDT 2025
Mon Jul 21 06:08:41 EDT 2025
Thu Apr 24 23:01:35 EDT 2025
Tue Jul 01 03:35:47 EDT 2025
Sat Sep 06 07:28:50 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Remimazolam
Propofol
Hip replacement
Elderly
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5885-fad870a63b3e511acf26a637801aa609b097e70cce4f4c1871e631f4dbf256443
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doi.org/10.1186/s12871-022-01641-5
PMID 35461223
PQID 2666636013
PQPubID 44060
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_2c1d6972304640dcaa350c8528083892
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9034563
proquest_miscellaneous_2655104970
proquest_journals_2666636013
gale_infotracmisc_A701420798
gale_infotracacademiconefile_A701420798
pubmed_primary_35461223
crossref_primary_10_1186_s12871_022_01641_5
crossref_citationtrail_10_1186_s12871_022_01641_5
springer_journals_10_1186_s12871_022_01641_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20220423
PublicationDateYYYYMMDD 2022-04-23
PublicationDate_xml – month: 4
  year: 2022
  text: 20220423
  day: 23
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC anesthesiology
PublicationTitleAbbrev BMC Anesthesiol
PublicationTitleAlternate BMC Anesthesiol
PublicationYear 2022
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References F Tang (1641_CR19) 2021; 9
J Schüttler (1641_CR16) 2020; 132
K Nakajima (1641_CR14) 2015; 52
H Li (1641_CR10) 2016; 53
T Ogawa (1641_CR17) 2020; 92
SE O'Bryant (1641_CR21) 2008; 65
X Pu (1641_CR5) 2019; 98
J Patel (1641_CR15) 2019; 7
AM Wesolowski (1641_CR18) 2016; 36
S Kawasaki (1641_CR6) 2018; 18
JR Sneyd (1641_CR13) 2020; 33
BM Luan Erfe (1641_CR3) 2018; 9
M Doi (1641_CR7) 2020; 34
A Lee (1641_CR20) 2021; 81
H Bozkurt (1641_CR9) 2019; 29
YS Lau (1641_CR1) 2020; 72
YH Lee (1641_CR2) 2020; 35
M Bantie (1641_CR4) 2020; 13
U Klotz (1641_CR12) 2009; 41
S Chen (1641_CR8) 2020; 12
X Xu (1641_CR11) 2020; 2020
References_xml – volume: 9
  start-page: 215145931881648
  year: 2018
  ident: 1641_CR3
  publication-title: Geriatr Orthop Surg Rehabil
  doi: 10.1177/2151459318816482
– volume: 29
  start-page: 705
  issue: 5
  year: 2019
  ident: 1641_CR9
  publication-title: Turk Neurosurg
– volume: 36
  start-page: 1021
  issue: 9
  year: 2016
  ident: 1641_CR18
  publication-title: Pharmacotherapy
  doi: 10.1002/phar.1806
– volume: 2020
  start-page: 5602683
  year: 2020
  ident: 1641_CR11
  publication-title: Pain Res Manag
  doi: 10.1155/2020/5602683
– volume: 18
  start-page: 167
  issue: 1
  year: 2018
  ident: 1641_CR6
  publication-title: BMC Anesthesiol
  doi: 10.1186/s12871-018-0633-2
– volume: 9
  start-page: 10595
  issue: 34
  year: 2021
  ident: 1641_CR19
  publication-title: World J Clin Cases
  doi: 10.12998/wjcc.v9.i34.10595
– volume: 132
  start-page: 636
  issue: 4
  year: 2020
  ident: 1641_CR16
  publication-title: Anesthesiology
  doi: 10.1097/ALN.0000000000003103
– volume: 7
  start-page: E625
  issue: 4
  year: 2019
  ident: 1641_CR15
  publication-title: Endosc Int Open
  doi: 10.1055/a-0829-6284
– volume: 92
  start-page: 301
  issue: 2
  year: 2020
  ident: 1641_CR17
  publication-title: Gastrointest Endosc
  doi: 10.1016/j.gie.2020.03.002
– volume: 34
  start-page: 543
  issue: 4
  year: 2020
  ident: 1641_CR7
  publication-title: J Anesth
  doi: 10.1007/s00540-020-02788-6
– volume: 33
  start-page: 506
  issue: 4
  year: 2020
  ident: 1641_CR13
  publication-title: Curr Opin Anaesthesiol
  doi: 10.1097/ACO.0000000000000877
– volume: 98
  issue: 16
  year: 2019
  ident: 1641_CR5
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000014925
– volume: 52
  start-page: 180
  issue: Pt A
  year: 2015
  ident: 1641_CR14
  publication-title: Epilepsy Behav
  doi: 10.1016/j.yebeh.2015.08.012
– volume: 81
  start-page: 1193
  issue: 10
  year: 2021
  ident: 1641_CR20
  publication-title: Drugs
  doi: 10.1007/s40265-021-01544-8
– volume: 12
  start-page: 4594
  issue: 8
  year: 2020
  ident: 1641_CR8
  publication-title: Am J Transl Res
– volume: 72
  start-page: 423
  issue: 3
  year: 2020
  ident: 1641_CR1
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.23838
– volume: 65
  start-page: 963
  issue: 7
  year: 2008
  ident: 1641_CR21
  publication-title: Arch Neurol
– volume: 41
  start-page: 67
  issue: 2
  year: 2009
  ident: 1641_CR12
  publication-title: Drug Metab Rev
  doi: 10.1080/03602530902722679
– volume: 53
  start-page: 487
  issue: 2
  year: 2016
  ident: 1641_CR10
  publication-title: J Alzheimers Dis
  doi: 10.3233/JAD-160119
– volume: 35
  start-page: 3517
  issue: 12
  year: 2020
  ident: 1641_CR2
  publication-title: J Arthroplast
  doi: 10.1016/j.arth.2020.06.085
– volume: 13
  start-page: 3139
  year: 2020
  ident: 1641_CR4
  publication-title: J Pain Res
  doi: 10.2147/JPR.S282462
SSID ssj0017803
Score 2.4959037
Snippet Objective To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on...
To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on respiratory and...
Objective To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects on...
Abstract Objective To explore the anesthetic and analgesic effects of remimazolam and propofol in elderly patients undergoing hip replacement and their effects...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 118
SubjectTerms Aged
Aged patients
Analgesics
Anesthesia
Anesthesia, General
Anesthesiology
Anesthetics
Benzodiazepines
Blood pressure
Cardiovascular disease
Cognition disorders
Cognitive ability
Corticosteroids
Cortisol
Critical Care Medicine
Elderly
Emergency Medicine
Epinephrine
Extubation
Fractures
General anesthesia
Health aspects
Heart beat
Heart rate
Hip
Hip replacement
Humans
Hydrocortisone
Intensive
Internal Medicine
Medicine
Medicine & Public Health
Norepinephrine
Patients
Phenols
Propofol
Propofol - adverse effects
Prospective Studies
Remimazolam
Respiration
Side effects
Statistical analysis
Surgery
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQqDwCpTISEgeI6vgV57ggqgoJTlTqCcvxg660m6x22wP8emacZNsUAReOu57ZtecRz8Tjbwh5HdqWeeZCGRH-UdYslo4pXsJm4p1TMbUe30N-_qLPzuWnC3Vxq9UX1oQN8MCD4E64r4LG1lh4BscC_IBQzBvFDQQPpslPX9jGpmRqPD-oDRPTFRmjT3YVJgYlVq4jpFRVqtk2lNH6f38m39qU7hZM3jk1zZvR6UPyYIwi6WKY_SNyL3aH5Nvi5jCajnUatE90G9fLtfsJOeyaui7QDTZGSP2KIhk26V79oCO86o7inbLt9x7-lV4uN8Cbi7bwFeJjcn768euHs3Jsn1B6ZYwqkwvgjE6LVkQIq5xPXMMnEE3lnGZNy5o61sz7KJP0FQgoalElGdoEcZCU4gk56PouPiM0KMzrtEmNcRKYTKVC8Mk7A-mV5qwg1SRN60dscWxxsbI5xzDaDhqwoAGbNWBVQd7ueTYDssZfqd-jkvaUiIqdvwBbsaOt2H_ZSkHeoIot-i5Mz7vxCgIsElGw7KKGhJGzujEFOZpRgs_5-fBkJHb0-Z2FUEcj-lolCvJqP4ycWMfWxf4aaSBChaSsBpE9HWxqvyShJISbHLjrmbXN1jwf6ZaXGRG8YQICYeB8N9nlzbT-LNPn_0OmL8h9nv1KllwckYOr7XV8CXHaVXucXfIXxmU1dw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LbtQw0IJy4YJAvFIKMhISB4hqO7bjnNCCqCokOFFpT1iO7bQr7SbLbnugX9-ZrJMlRfSYeEaJ5-GZscczhLwLdc08cyGPWP5RlizmjimRgzHxzqnY1B73Ib__0Kdn8ttczdOG2zalVQ5rYr9Qh87jHvkxGBKNta148Wn9O8euUXi6mlpo3CcPOLgqKNXlfAy4eGlYMVyUMfp4yzE8yDF_HQtL8VxNjFFfs__flfkv03Q7bfLW2Wlvkk4ek0fJl6SzHfOfkHuxfUp-zfZH0jRla9CuoZu4WqzcNUSyK-raQNfYHqHplhTBsFX38g9NRVa3FG-Wbc47-Cq9WKwBt0_dwo3EZ-Ts5OvPL6d5aqKQe2WMyhsXQCWdLuoignPlfCM0PAFpuHOaVTWrylgy76NspOdAoKgL3shQN-ANSVk8Jwdt18aXhAaF0Z02TWWcBCTDVQi-8c5AkKUFywgfqGl9qjCOjS6Wto80jLY7DljggO05YFVGPow46119jTuhPyOTRkisjd2_6DbnNqmaFZ4Hjc3U8NSWBRC5QjFvlDDgbppKZOQ9stiiBsPveZcuIsAksRaWnZUQNgpWViYjRxNI0Dw_HR6ExCbN39q9nGbk7TiMmJjN1sbuCmHAT4XQrASSvdjJ1DilQklwOgVglxNpm8x5OtIuLvq64BUrwB0GzI-DXO5_6_80Pbx7Fq_IQ9FrjMxFcUQOLjdX8TX4YZf1m17ZbgDvxi7G
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1di9QwMJwniC_it9VTIgg-aDVNkzR9EFnF4xDWJxfuyZCmyd3Cbrt278Dz1zuTbXfteQo-tpmBZD46M53JDCEv6qpijtk69dj-URTMp5ZJnoIxcdZKHyqH_yGnX9TRTHw-lsd7ZBh31BNwfWVoh_OkZt3izY_vF-9B4d9Fhdfq7TpDtz_FunRsGJWl8hq5DpaJo5RPxS6rUGiWDxdnrsQbGafYw__PL_VvpupyGeWlXGo0UYe3ya3et6STjTDcIXu-uUtuTPvs-T3ybbLLVtO-kIO2gXZ-OV_an0CJJbVNTVc4OSG0C4pgOMV7cUH7_qtripfOupMWNkBP5yvAjVVd-I_xPpkdfvr68Sjt5yukTmot02Br0Far8ir34HdZF7iCJ6BSZq1iZcXKwhfMOS-CcBnQyqs8C6KuAjhKQuQPyH7TNv4RobXEwE_pUGorAElnsq5dcFZD_KU4S0g2ENa4vvk4zsBYmBiEaGU2zDDADBOZYWRCXm1xVpvWG_-E_oD82kJi2-z4ou1OTK-FhrusVjhnDRO6rAZpzCVzWnINnqgueUJeIrcNihtsz9n-jgIcEttkmUkBESVnRakTcjCCBKV04-VBXswg0wZ8IYXt2bI8Ic-3y4iJhW6Nb88RBlxYiNoKINnDjXhtj5RLAf4oB-xiJHijM49XmvlpbBleshw8ZcB8PYjoblt_p-nj_wN_Qm7yqEwi5fkB2T_rzv1TcNnOqmdRD38B3Pg5YA
  priority: 102
  providerName: Scholars Portal
Title Application effects of remimazolam and propofol on elderly patients undergoing hip replacement
URI https://link.springer.com/article/10.1186/s12871-022-01641-5
https://www.ncbi.nlm.nih.gov/pubmed/35461223
https://www.proquest.com/docview/2666636013
https://www.proquest.com/docview/2655104970
https://pubmed.ncbi.nlm.nih.gov/PMC9034563
https://doaj.org/article/2c1d6972304640dcaa350c8528083892
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMedCentral
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: RBZ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: KQ8
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: KQ8
  dateStart: 20011001
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: ABDBF
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: DIK
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: RPM
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: M48
  dateStart: 20011001
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: Springer Nature HAS Fully OA
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: AAJSJ
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: C6C
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1471-2253
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017803
  issn: 1471-2253
  databaseCode: U2A
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swEBdrC2MvY9_z1gUNBnvYzCRZkuXHJLSUQcooC4Q9TMiy3AYSOyTtw_rX985x3Lr7gL0IEt2BpLuz7nSnnwj5UOQ588wVcUD4R5myEDumRAybiXdOhTL3eA45OdUnU_l1pmYtTA7ehbmbv-dGf9lwdOljrDlHMCgeqz1yoODDi-V7Yz3uMgapYcnuUswf-XobT4PP__tX-M42dL9E8l6etNl-jp-Qx63fSIdbQT8lD0L1jDyctJnx5-Tn8DYTTdsiDVqXdB2W86W7hgB2SV1V0BW-ilDWC4pk-EL34hdtsVU3FC-Urc9rGAC9mK-At6nYwvPDF2R6fPR9fBK3byfEXhmj4tIVYIlOJ3kSwKdyvhQafsEqcec0y3KWpSFl3gdZSs9hrYJOeCmLvAQnSMrkJdmv6iq8JrRQGNRpU2bGSWAyXBWFL70zEFtpwSLCdwtrfQssju9bLGwTYBhtt8KwIAzbCMOqiHzqeFZbWI1_Uo9QXh0lQmI3f4Cm2NbCrPC80PiGGiZrWQGalijmjRIGvEyTiYh8RGlbNFwYnnft_QOYJEJg2WEK0aJgaWYictijBIPz_e6dvtjW4DcW_ByN0Gs8icj7rhs5sYitCvUV0oB7ChFZCkv2aqte3ZQSJcHXFMCd9hSvN-d-TzW_aODAM5aAFwycn3cqejusv6_pm_8jf0seicaYZCySQ7J_ub4K78Adu8wHZC-dpQNyMDo6_XY2aKxy0BxtQDuRBtqz0Q9op2J4AyK7MRc
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0CrlABcE4hUoYCQQB4jqOLbjHBBaHtWWPk6ttCeMYzvtSrvJstsKlY_iG5nJJrukiN563HgmG3ve9niGkFe-KJhj1scByz-KjIXYMsljMCbOWhnKwuE-5MGhGh6LryM52iC_u7swmFbZ6cRGUfva4R75NhgShbWtkvTD7EeMXaPwdLVrobFki71w8RNCtsX73c9A39ec73w5-jSM264CsZNay7i0HnjUqrRIA3gb1pVcwa8MVLW1iuUFy7OQMeeCKIVLIKAIKk1K4YsS3AMhUnjvDXJTpExgrf5stArwEnhH2l3M0Wp7kWA4EmO-PBaySmLZM35Nj4B_LcFfpvBymuals9rGBO7cJXda35UOlsx2j2yE6j75NlgfgdM2O4TWJZ2H6Xhqf0HkPKW28nSG7RjKekIRDFuDTy5oW9R1QfEm2_ykhn-lp-MZ4DapYrhx-YAcX8vyPiSbVV2Fx4R6idGk0mWurQAknUjvXemshqBOcRaRpFtN49qK5thYY2KayEYrs6SAAQqYhgJGRuTtCme2rOdxJfRHJNIKEmtxNw_q-YlpRdtwl3iFzdvwlJh5YPFUMqcl1-De6pxH5A2S2KDGgM9ztr34AJPE2ltmkEGYylmW64hs9SBB0l1_uGMS02qahVnLRUReroYRE7PnqlCfIwz4xRAKZrBkj5Y8tZpSKgU4uRywsx639ebcH6nGp00d8pyl4H4D5ruOL9ef9f81fXL1LF6QW8Ojg32zv3u495Tc5o30iJinW2TzbH4enoEPeFY8bwSPku_XLel_AGm2auA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwELaglSpeUDkbWsBISDxAVOew4zyGY1UWWiFBpT5hOT7alXaT1e72AX49M7nalEPiMfGMZHtm4pnM-BtCXtqyZIZpGzqEf0wz5kLNeBzCYWK05s6XBv9DHp-Io9N0esbPrt3ib6rd-5Rke6cBUZqqzeHS-tbEpThcR-joh1iJjhBRUchvk23JcwHh13ZRTL9Oh0xCJlnSX5b5I-foQGpw-3__Ol87nm6WTt7InzbH0mSX3O38SVq0CnCP3HLVfbJz3GXMH5DvxVWGmnbFG7T2dOUWs4X-CYHtgurK0iV2S_D1nCIZdu6e_6Ad5uqa4kWz1XkNE6AXsyXwNpVc-F_xITmdfPj27ijseiqEhkvJQ68tWKgWSZk48LW08bGAJ9ilSGvB8pLlmcuYMS71qYlgr5xIIp_a0oNzlKbJI7JV1ZXbI9RyDPaE9LnUKTDJiFtrvNESYi4Rs4BE_cYq0wGOY9-LuWoCDylUKwwFwlCNMBQPyOuBZ9nCbfyT-i3Ka6BEqOzmRb06V53lqdhEVmBvNUziMgsamHBmJI8leJ8yjwPyCqWt0KBhekZ39xJgkQiNpYoMosiYZbkMyMGIEgzRjId7fVHdh2CtwP8RCMkWJQF5MQwjJxa3Va6-RBpwWyFSy2DLHrfqNSwp4Sn4oDFwZyPFG615PFLNLhqY8Jwl4B0D55teRa-m9fc9ffJ_5M_Jzpf3E_X548mnfXInbuwqDePkgGxtVpfuKXhsm_JZZ5S_ABOJN3o
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Application+effects+of+remimazolam+and+propofol+on+elderly+patients+undergoing+hip+replacement&rft.jtitle=BMC+anesthesiology&rft.au=Zhang%2C+Junbao&rft.au=Wang%2C+Xin&rft.au=Zhang%2C+Qing&rft.au=Wang%2C+Zicheng&rft.date=2022-04-23&rft.pub=BioMed+Central&rft.eissn=1471-2253&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12871-022-01641-5&rft.externalDocID=10_1186_s12871_022_01641_5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2253&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2253&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2253&client=summon